The prevalence of two genetic traits related to venous thrombosis in Whites and African-Americans

Thrombosis Research

Volumn 86, Issue 5, 1997, Pages 409-415

  Austin, Harland ^a,b   Hooper, W Craig ^a   Dilley, Anne ^a,c   Drews, Carey ^b   Renshaw, Mary ^a   Ellingsen, Dorothy ^a   Evatt, Bruce ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Factor V Leiden; MTHFR gene; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5;

ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CAUCASIAN; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; NEWBORN; PREVALENCE; PRIORITY JOURNAL; VEIN THROMBOSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; EPIDEMIOLOGY, MOLECULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR V; FEMALE; GENE FREQUENCY; GEORGIA; HETEROZYGOTE; HUMANS; INFANT, NEWBORN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; THROMBOPHLEBITIS; VARIATION (GENETICS);

EID: 0030850024     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00086-8     Document Type: Article

References (19)

1. DAHLBACK, B., CARLSSON, M. and SVENSSON, P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 90, 1004-1008, 1993.
2. DAHLBACK, B. and HILDEBRAND B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci 91, 1396-1400, 1994.
3. BERTINA, R.M., KOELEMAN, B.P.C., KOSTER, T., ROESENDAAL, F.R., DIRVEN, R.J., de RONDE, H., van der VELDEN, P.A. and REITSMA, P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67, 1994
4. KOSTER, T., ROSENDAAL, F.R., de RONDER, H., BRIET, E., VANDENBROUCKE, J.P. and BERTINA, R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 34, 1503-1506, 1993.
5. SVENSSON, P.J. and DAHLBACK, B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330, 517-522, 1994.
6. RIDKER, P.M., HENNEKENS, C.H., LINDPAINTNER, K., STAMPFER, M.J., EISENBERG, P.R. and MILETICH, J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332, 912-917, 1995.
7. FROSST, P., BLOM, H.J., MILOS, R., GOYETTE, P., SHEPPARD, C.A., MATTHEWS, R.G., BOERS, G. J.H., VAN DEN HEUVEL, L.P. and ROZEN, R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 10, 111-113, 1995.
8. FALCON, C.R., CATTANEO, M., PANZERI, D., MARTINELLI, I. and MANNUCCI, P.M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14, 1080-1083, 1994.
9. FERMO, I., D'ANGELO, S.V., PARONI, R., MAZZOLA, G., CALORI, G., and D'ANGELO, A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 123 747-753, 1995.
10. DEN HEIJER M, KOSTER T, BLOM HJ, BOS GM, BRIET E, REITSMA PH, VANDENBROUCKE, J.P. and ROSENDAAL, F.R. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334, 759-762, 1996.
11. DILLEY, A. Unpublished Doctoral Dissertation, Department of Epidemiology, Emory University School of Public Health, 1995.
12. SNEDECOR, G.W. and COCHRAN, W. Statistical Methods. Seventh Edition. Iowa State University Press, Ames, Iowa, 1980.
13. MCANDREW, P.E., BRANDT, J.T., PEARL, D.K., and PRIOR, T.W. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thrombosis Research 83, 195-198, 1996.
14. STEVENSON, R.E., SCHWARTZ, C.E., DU, Y. and ADAMS, M.J. Difference in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 60, 228-229, 1997.
15. ROSENDAAL, F.R., KOSTER, T., VANDENBROUCKE, J.P., and REITSMA, P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein resistance). Blood 85, 1504-1508, 1995.
16. KONTULA, K., YLIKORKALA, A., MIETTINEN, H., VUORIO, A., KAUPPINEN-MAKELIN, R., HAMALAINEN, L., PALOMAKI, H. and KASTE, M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thrombosis Haemost 73, 558-560, 1995.
17. REES, D.C. COX, M and CIEGG, J.B. World distribution of factor V Leiden. Lancet 346, 1133-34, 1995.
18. HOOPER, W.C., DILLEY, A., RIBEIRO, M.J.A., BENSON, J., AUSTIN, H., SILVA, V., RAWLINS, P., WENGER, N.K. and EVATT, B.L. A racial difference in the prevalence of the Arg506>Gln mutation Thromb Res 81, 577-581, 1996.
19. KNIFFIN, W.D., BARON, J.A., BARRETT, J., BIRKMEYER, J.D. and ANDERSON, F.A. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154, 861-866, 1994.